fda approvals in ntrk fusion tumors, ros1 nsclc, and myelofibrosis, and more
Published 4 years ago • 142 plays • Length 13:43Download video MP4
Download video MP3
Similar videos
-
10:29
fda approval in melanoma, priority review in dlbcl, rcc, and ntrk fusion–positive tumors
-
0:40
evaluating next steps for entrectinib in ros1-positive nsclc
-
4:27
entrectinib: a review in ntrk solid tumours and ros1 nsclc
-
50:46
selective, potent, different: next-generation ros1 and trk inhibition in nsclc and other tumors
-
1:07
dr. subbiah on the fda approval of pralsetinib in ret nsclc
-
7:28
fda approvals in pml, nsclc, and breast cancer, priority review in dlbcl, and more
-
7:02
fda approval of selpercatinib for ret fusion positive nsclc and thyroid cancers
-
5:54
two fda approvals, braf/mek breakthrough status in nsclc, and more
-
4:05
case of an ntrk fusion-positive lung cancer patient
-
1:36
fda approval of durvalumab for stage iii unresectable nsclc
-
5:08
larotrectinib for ntrk fusions: patient selection
-
2:53
entrectinib in ntrk fusion-positive non-small cell lung cancer
-
7:18
full fda approvals in breast cancer and lung cancer, priority reviews in all, and more
-
2:17
dr. paz-ares on entrectinib in ntrk fusion-positive nsclc
-
14:30
the detection of ntrk gene fusions in nsclc
-
1:02
how are ntrk gene fusions treated?
-
6:11
testing in ntrk fusion-positive lung cancer
-
1:15
dr. spigel on fda approval of pembrolizumab/chemo combo in nsclc
-
1:25
dr. bazhenova on prevalence of ntrk mutations in nsclc